Polaryx Therapeutics (NASDAQ:PLYX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Polaryx Therapeutics (NASDAQ:PLYX) from a sell rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

Several other research analysts have also recently weighed in on PLYX. Weiss Ratings raised Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They set a “buy” rating and a $7.00 target price for the company. Zacks Research upgraded Polaryx Therapeutics to a “hold” rating in a research note on Friday, July 10th. Finally, Raymond James Financial started coverage on shares of Polaryx Therapeutics in a report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Polaryx Therapeutics Stock Performance

NASDAQ:PLYX opened at $2.02 on Friday. Polaryx Therapeutics has a 52 week low of $1.85 and a 52 week high of $48.91. The firm has a 50-day moving average price of $2.17 and a two-hundred day moving average price of $3.44. The firm has a market cap of $100.70 million and a price-to-earnings ratio of -25.25.

Polaryx Therapeutics (NASDAQ:PLYX) last announced its earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. As a group, sell-side analysts forecast that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.